InvestorsHub Logo

MP_CES

04/25/15 11:52 AM

#110722 RE: NRC #110720

Gee I wonder who Dr. Seymour was referring to? LOL

Could it possibly be the guy who said...

"Why is retired professor's work being touted when, if he did work on anything with NNVC "recently" the most recent would have been in 2013?"

The guy who said this is clearly implying that the PR was from a study done years ago. The PR clearly states that is was recent. The PR also states that it was done in the "lab of Dr. Rosenthal" not "by Dr. Rosenthal.

It also states he is now 'Professor Emeritus' which clearly states he is retired as that's what Professor Emeritus means. Professor Emeritus is still involved on consultation purposes as anyone would know that no one is going to walk away completely from a lifetime of work.

Dr. Rosenthal's comments were made after the study was done in the lab named after him which still and will always exist. He was consulted and made the comments that the cides were clearly preventing the breakout which is the main problem with humans having herpes.

At least 50 percent of the global population live with the virus in their nervous system. The breakouts affect over 1 billion people (shingles, cold sores, genital herpes). Chicken pox is the same virus and if anyone that is suffering from shingles (the recurring breakouts of the herpes/chicken pox virus) could stop the breakouts and ease their suffering they would be all over it like a hobo on a ham sandwich.

This market is producing over 900 Million dollars in revenue to the top three drugs which are only 2 percent effective. Should the continued studies show the 90 percent rate NNVC has achieved the market size would be much much larger. Very few are opting for the current drugs because they simply don't work.